BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

CyDex, Inc. 

12980 Metcalf Avenue, Suite 470

Overland Park  Kansas  66213  U.S.A.
Phone: 913-685-8850 Fax: 913-685-8856


SEARCH JOBS

View Clinical Trials from BioPharm Insight




Segment
Drug Delivery

Collaborations

TargeGen, Inc.  Licensing Agreement





 Company News
Ligand Pharmaceuticals Inc. (LGND) Buys CyDex, Inc. For $31.2M Upfront In Cash 1/27/2011 6:36:02 AM
CyDex, Inc. Announces New Corporate Name 11/20/2007 10:56:43 AM
Pediatric Asthma Programs With CyDex, Inc. Captisol Technology Acquired by AstraZeneca PLC (AZN) 10/3/2007 8:52:08 AM
Aradigm Corporation (ARDM) and CyDex, Inc. Sign Development Collaboration Agreement 9/6/2007 10:58:43 AM
CyDex, Inc. Licenses Captisol(R) to Critical Therapeutics for Injectable Formulation of Zileuton 6/12/2007 2:12:35 PM
CyDex, Inc. Licenses Captisol(R) to Sunesis Pharmaceuticals, Inc. (SNSS) for Oncology Drug Candidate 5/3/2007 12:20:17 PM
CyDex, Inc. Licenses Captisol(R) to Proteolix, Inc. for Promising Oncology Compound 5/1/2007 12:23:23 PM
CyDex, Inc. Announces Captisol Technology Used in Injection Formulation of Veterinary Anti-Emetic Cerenia(R) (Maropitant) Recently Approved for Marketing in Europe 4/10/2007 12:32:50 PM
CyDex, Inc. Announces Captisol Technology Used In Recently Launched Injection Formulation Of Antipsychotic Medication ABILIFY(R) (aripiprazole) 12/18/2006 3:49:17 PM
CyDex, Inc. Announces Captisol Technology Used In Recently Launched Injection Formulation Of Antipsychotic Medication ABILIFY(R) (aripiprazole) 12/14/2006 11:35:10 AM
12